Ratings Harbin Fuerjia Technology Co., Ltd.

Equities

301371

CNE1000066F0

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
36.94 ^CNY	-2.22%		+6.79%	-3.32%

Apr. 26	Harbin Fuerjia Technology Co., Ltd. Announces Profit Distribution Proposal of Cash Dividend for 2023	CI
Apr. 25	Harbin Fuerjia Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HARBIN FUERJIA TECHNOLOGY CO., LTD.	-3.32%	2.05B		-
COLOPLAST A/S	+9.48%	27.38B		B+
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	-29.57%	3.08B		B-
INTCO MEDICAL TECHNOLOGY CO., LTD.	+17.21%	2.45B	-	A-
WINNER MEDICAL CO., LTD.	-16.72%	2.51B		C+
HARTALEGA HOLDINGS	+7.78%	2.09B		B
TOP GLOVE CORPORATION BHD.	+2.22%	1.55B		B
NAKANISHI INC.	+0.42%	1.29B		-
KOSSAN RUBBER INDUSTRIES	+23.24%	1.23B		C
KANGJI MEDICAL HOLDINGS LIMITED	+6.29%	1.13B		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes